16 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Hospira, the world's leading provider of injectable drugs and infusion technologies, has appointed Dr Matthew R Stober as senior vice president of operations.
In addition to expanding his current US responsibilities to assume leadership for all of Hospira's pharmaceutical manufacturing operations, Mr Stober will have responsibility for the operations functions, including manufacturing science and technology, engineering, competitive strategy, health and safety, supply chain and procurement.
He joined Hospira from Johnson & Johnson, where he served as the vice president and global platform leader for solids, parenterals and vaccines. Mr Stober has extensive experience managing transformational change in business-critical settings, as well as leading global and multi-company development projects, new product launches and large-scale organizational transformations. He has been in the pharmaceutical industry for nearly 25 years, having held significant leadership roles at Novartis Vaccines and Diagnostics, GlaxoSmithKline and Merck.
Mr Stober succeeds Mr John B Elliot, who has led the operations of the organization since April 2012 and will provide continuity of support until his retirement at the end of the year. Both Mr Elliot and Mr Stober will serve as members of the company's senior leadership team, led by Mr Michael Ball, the chief executive officer.
"Matt brings the perfect blend of vision and experience to our operations organization, backed by a proven track record of success at Hospira," said Mr Ball. "In his expanded role, we're confident Matt will continue to successfully advance our dual commitment to remediate and modernize our processes and operations while delivering patient-critical products, and ultimately establish our manufacturing operations as a strategic, competitive advantage."